Last reviewed · How we verify
Extended course macrolide — Competitive Intelligence Brief
phase 3
Macrolide antibiotic (anti-inflammatory/immunomodulatory use)
Respiratory/Pulmonology
Small molecule
Live · refreshed every 30 min
Target snapshot
Extended course macrolide (Extended course macrolide) — UMC Utrecht. Extended course macrolide antibiotics reduce airway inflammation and modulate immune responses in chronic respiratory conditions through anti-inflammatory and immunomodulatory effects.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Extended course macrolide TARGET | Extended course macrolide | UMC Utrecht | phase 3 | Macrolide antibiotic (anti-inflammatory/immunomodulatory use) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Macrolide antibiotic (anti-inflammatory/immunomodulatory use) class)
- UMC Utrecht · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Extended course macrolide CI watch — RSS
- Extended course macrolide CI watch — Atom
- Extended course macrolide CI watch — JSON
- Extended course macrolide alone — RSS
- Whole Macrolide antibiotic (anti-inflammatory/immunomodulatory use) class — RSS
Cite this brief
Drug Landscape (2026). Extended course macrolide — Competitive Intelligence Brief. https://druglandscape.com/ci/extended-course-macrolide. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab